Sort
10,766 grants matching “checkpoint inhibitor”
Mechanisms of Immune-mediated Tumor Cell Destruction
$303,991Thomas Sayers · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Prostate cancer chemoprevention by penta-galloyl-glucose
$303,925Junxuan Lu · Texas Tech University Health Scis Center · R01 · FY2012 · CA
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
$303,810Alan R Eastman · Dartmouth College · R01 · FY2008 · CA
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
$303,810Alan R Eastman · Dartmouth College · R01 · FY2007 · CA
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
$303,810Alan R Eastman · Dartmouth College · R01 · FY2009 · CA
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
$303,810Alan R Eastman · Dartmouth College · R01 · FY2010 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma
$303,780Charles Keller · Children'S Cancer Therapy Develop/Inst · R01 · FY2025 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma
$303,780Charles Keller · Children'S Cancer Therapy Develop/Inst · R01 · FY2021 · CA
Roles of Lig3 and XRCC1 Genes in Genome Stability
$303,750Alan E Tomkinson · University Of Maryland Baltimore · R01 · FY2009 · ES
Role of RecQ Helicases to Prevent Senescence By c-Myc
$303,731Carla Grandori · Fred Hutchinson Cancer Research Center · R01 · FY2008 · AG
Role of RecQ Helicases to Prevent Senescence By c-Myc
$303,731Carla Grandori · Fred Hutchinson Cancer Research Center · R01 · FY2009 · AG
Project 1: Treatment of GBM using an oncolytic HSV engineered to improve immunogenic tumor destruction
$303,659Joseph C. Glorioso · Brigham And Women'S Hospital · P01 · FY2025 · CA
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)
$303,523Jean Zhao · Brigham And Women'S Hospital · P50 · FY2023 · CA
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)
$303,523Jean Zhao · Brigham And Women'S Hospital · P50 · FY2022 · CA
Role of the Acetyltransferase p300 in Cellular Responses
$303,484Maria L Avantaggiati · Georgetown University · R01 · FY2006 · CA
Ultralong CDR3 antibodies targeting exhausted T cells
$303,450Vaughn Vasil Smider · Applied Biomedical Science Institute · R21 · FY2020 · AI
Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit
$303,194Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2012 · CA
P34CDC2 AND CELL CYCLE CONTROL
$303,189Washington University · R01 · FY2001 · GM
Project 3: Mechanisms of immunotherapy action
$303,065Marcia Haigis · Harvard Medical School · U54 · FY2018 · CA
The Mammalian Cell Cycle Control and Tumor Genesis
$302,959Yue Xiong · Univ Of North Carolina Chapel Hill · R01 · FY2006 · CA
The Werner syndrome protein in CPT-induced DNA damage
$302,926Lucio Comai · University Of Southern California · R01 · FY2007 · AG
Development Therapeutics Branch Clinical Trials
$302,851Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$302,654Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2021 · CA
Therapeutic targeting of HSP90-dependent signaling
$302,375Mayo Clinic · R01 · FY2004 · CA
Re-replication of chromosomes and cancer
$302,345Anindya Dutta · University Of Virginia · R01 · FY2013 · CA